Meeting Banner
Abstract #3178

MR Spectroscopy as an Early Indicator of Response to Anti-Angiogenic Therapy in Patients with Recurrent Glioblastoma: ACRIN 6677 / RTOG 0625

Eva-Maria Ratai1, Zheng Zhang2, Bradley Snyder2, Melanie Yeh2, Darryl L'Heureux3, Jamie Downs3, Jerrold Boxerman4, Yair Safriel5, Gregory Sorensen1, Daniel

1Department of Radiology, A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital , Charlestown, MA, United States; 2Center for Statistical Sciences, Brown University, United States; 3American College of Radiology Imaging Network, United States; 4Diagnostic Imaging, Warren Albert Medical School of Brown University, United States; 5Radiology Associates of Clearwater, United States; 6Department of Radiology, Duke University Medical Center, United States; 7Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, United States

We here report the MR spectroscopy findings of the clinical trial RTOG 0625/ACRIN 6677 entitled A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in Recurrent Glioblastoma The purpose of this study was to assess the potential role of MR spectroscopy as an early indicator of response to anti-angiogenic therapy. We find transient decreases in choline/creatine (Cho/Cr) at 2 weeks post treatment indicating a possible decrease in tumor malignancy. Furthermore, after 8 weeks of anti-angiogenic therapy decreases in Cho/Cr in the tumor and increases in N-Acetylaspartate/Cr in the periphery are associated with 12-month survival.